Andrew B Lassman

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
    Andrew B Lassman
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Neuro Oncol 13:649-59. 2011
  2. ncbi Molecular biology of gliomas
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Neurol Neurosci Rep 4:228-33. 2004
  3. ncbi Incorporating molecular tools into clinical trials and treatment for gliomas?
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Opin Neurol 20:708-11. 2007
  4. ncbi Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 11:7841-50. 2005
  5. ncbi Systemic high-dose intravenous methotrexate for central nervous system metastases
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 78:255-60. 2006
  6. ncbi Metastases to the pineal gland
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 67:1303-4. 2006
  7. pmc Initial treatment patterns over time for anaplastic oligodendroglial tumors
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
    Neuro Oncol 14:761-7. 2012
  8. pmc A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:95-103. 2010
  9. pmc Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1244-51. 2011
  10. doi Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 105:607-12. 2011

Detail Information

Publications33

  1. pmc International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
    Andrew B Lassman
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Neuro Oncol 13:649-59. 2011
    ..Combined CT + RT led to longer disease control and survival than did CT or RT alone in cases with no 1p19q deletion. Ongoing trials will address these issues prospectively...
  2. ncbi Molecular biology of gliomas
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Neurol Neurosci Rep 4:228-33. 2004
    ..Each of these abnormalities is described in detail. Efforts to inhibit abnormally activated pathways are underway through multi-institutional clinical trials...
  3. ncbi Incorporating molecular tools into clinical trials and treatment for gliomas?
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Opin Neurol 20:708-11. 2007
    ..Knowledge of the molecular biology of gliomas may improve therapy. This review highlights several recent studies on this topic...
  4. ncbi Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 11:7841-50. 2005
    ....
  5. ncbi Systemic high-dose intravenous methotrexate for central nervous system metastases
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 78:255-60. 2006
    ..Rapid infusion of high-dose intravenous methotrexate (HD IV MTX) penetrates the blood-brain barrier (BBB) and has reported activity in leptomeningeal metastases...
  6. ncbi Metastases to the pineal gland
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 67:1303-4. 2006
    ..Hence, metastatic disease, albeit uncommon, should be considered in the differential diagnosis of pineal tumors...
  7. pmc Initial treatment patterns over time for anaplastic oligodendroglial tumors
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
    Neuro Oncol 14:761-7. 2012
    ..01), and frontal lobe predominance (P < .05). Limited level 1 evidence is currently available to guide treatment decisions, and ongoing phase III trials will be critical to understanding the optimal therapy...
  8. pmc A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:95-103. 2010
    ..001). Single-agent activity of erlotinib is minimal for recurrent MGs and marginally beneficial following RT for NP GBM patients. Development of rash in cycle 1 correlates with survival in patients with NP GBM after RT...
  9. pmc Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1244-51. 2011
    ..4, P< .0001). Longitudinal increases in serum YKL-40 are associated with increased risk of death in patients with glioblastomas and anaplastic gliomas. YKL-40 is also a putative indicator of disease status in these patients...
  10. doi Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 105:607-12. 2011
    ..Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival...
  11. pmc Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 15:242-50. 2013
    ..In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)...
  12. doi Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma
    Lauren Q Shapiro
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Int J Radiat Oncol Biol Phys 85:636-42. 2013
    ..The objective of this study was to characterize the patterns of failure after this treatment regimen...
  13. pmc "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
    Christian Grommes
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1364-9. 2011
    ..Pulsatile erlotinib can control CNS metastases from EGFR mutant lung cancer after failure of standard daily dosing. CNS disease may not harbor acquired resistance mutations that develop systemically. A prospective trial is planned...
  14. pmc Survey of treatment recommendations for anaplastic oligodendroglioma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 9:314-8. 2007
    ....
  15. pmc A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:87-94. 2010
    ..This has important implications for further development of this drug in the treatment of MG as well as the optimal management of patients with other malignancies such as NSCLC who are on enzyme-inducing drugs...
  16. ncbi A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    J Neurooncol 87:85-90. 2008
    ..To investigate the efficacy and safety of the combination of vinorelbine and intensive temozolomide for recurrent or progressive brain metastases from solid tumors...
  17. doi High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
    Jennifer L Clarke
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 99:283-6. 2010
    ..However, intermittent (pulsatile) high dose administration (1000-1500 mg/week) achieves a higher CSF concentration than standard dosing, and successfully controlled LM in this patient...
  18. pmc Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma
    Jennifer L Clarke
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA
    J Clin Oncol 27:3861-7. 2009
    ..The goal of this randomized phase II study was to evaluate two different temozolomide regimens in the adjuvant treatment of newly diagnosed GBM...
  19. doi Steroid management in newly diagnosed glioblastoma
    Mariel B Deutsch
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 113:111-6. 2013
    ..Steroids are often tapered during RT, but there is frequent taper failure with this approach. A prospective trial with standardized steroid dosing regimens would be needed to verify these findings...
  20. pmc Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors
    Igor Vivanco
    Human Oncology and Pathogenesis Program, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Discov 2:458-71. 2012
    ....
  21. doi Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status
    Marsha Reyngold
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 110:369-74. 2012
    ..Grade 3-4 hematologic toxicity occurred in 11 patients. Abbreviated RT with concurrent TMZ provides a clinical benefit, is safe and tolerable in patients of advanced age or poor functional status...
  22. doi Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors
    Samuel A Goldlust
    Department of Neurology and the Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 107:407-11. 2012
    ..Prior exposure to VEGFR-TKIs may not preclude response to BEV, but sensitivity to BEV may be lower following more robust VEGFR inhibition...
  23. doi YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma
    Andreas F Hottinger
    Brain Tumor Center, New York, NY, USA
    Ann Neurol 70:163-9. 2011
    ..To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL)...
  24. ncbi Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas
    Gaurav D Shah
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Neurooncol 85:217-22. 2007
    ..Disease control may also correlate with hematologic toxicity (p = 0.08), suggesting that glioma and marrow stem cells may share a common sensitivity to this chemotherapy regimen...
  25. pmc Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
    Kevin C De Braganca
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Neurooncol 100:443-7. 2010
    ..This series suggests bevacizumab may be safe and effective for progressive brain metastases from NSCLC and deserves further study...
  26. doi Signal transduction inhibitors and antiangiogenic therapies for malignant glioma
    Ingo K Mellinghoff
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA
    Glia 59:1205-12. 2011
    ..2011 Wiley-Liss, Inc...
  27. doi Success at last: a molecular factor that informs treatment
    Andrew B Lassman
    Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10538, USA
    Curr Oncol Rep 15:47-55. 2013
    ..g. IDH mutation and MGMT promoter methylation) that occurred in the interim emphasize the need for earlier, validated, and acceptable trial end points...
  28. ncbi Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions
    Douglas E Ney
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Oncol Rep 11:62-7. 2009
    ..Other molecular alterations found in oligodendrogliomas include hypermethylation of the promoter for the MGMT gene, TP53 mutations, EGFR and platelet-derived growth factor/PDGFR alterations, and 9p and 10q loss...
  29. doi Advances in the treatment of malignant gliomas
    Mustafa Khasraw
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Oncol Rep 12:26-33. 2010
    ..This review focuses on recent advances in the treatment malignant gliomas, especially antiangiogenic therapy...
  30. ncbi Glioma oncogenesis and animal models of glioma formation
    Yelena Lyustikman
    Department of Cancer Biology, Memorial Sloan Kettering Cancer Center, 408 East 69th Street, Z1319, New York, NY 10021, USA
    Hematol Oncol Clin North Am 20:1193-214. 2006
    ..Animal models are important not only for the testing of novel therapeutics but also as a means to understand the molecular explanations for treatment success and failure in humans...
  31. ncbi Brain metastases
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Neurol Clin 21:1-23, vii. 2003
    ..This article reviews the epidemiology, clinical features, treatment, and prognosis of brain metastases from system malignancies...
  32. ncbi Response of glioblastomas to EGFR kinase inhibitors
    Andrew B Lassman
    N Engl J Med 354:525-6; author reply 525-6. 2006
  33. ncbi Salvage temozolomide for prior temozolomide responders
    Enrico Franceschi
    Department of Medical Oncology, Bellaria Hospital, Bologna, Italy
    Cancer 104:2473-6. 2005
    ..In the current study, the authors assessed the outcome and complications of reusing TMZ at the time of disease recurrence in patients who previously responded to treatment...